3 Premium Motorcycle Maker, Pharmaceutical Ingredients Maker and Air Compressor Maker Stocks With a Strong Future Roadmap: Eicher Motors, Granules India and Elgi Equipments
- November 13, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Eicher Motors, Granules India and Elgi Equipments: ROE of 11.7% to 22.0% and FY22 to FY26 revenue CAGR of 9.2% to 23.4%. Prices as of 12 Nov 2026.
Quick Answer
The three bike, pharma ingredient and compressor stocks to watch are Eicher Motors, Granules India and Elgi Equipments. Their return on equity ranges from 11.7% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 23.4%. Eicher Motors leads on both return on equity at 22.0% and revenue growth at 23.4% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.
Bike, pharma ingredient and compressor stocks let investors follow companies that serve a growing part of the Indian economy. Eicher Motors, Granules India and Elgi Equipments cover a premium motorcycle maker, a pharmaceutical ingredients maker and an air compressor maker.
This list covers three bike, pharma ingredient and compressor stocks with complete current figures: Eicher Motors, Granules India and Elgi Equipments. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Bike, Pharma Ingredient and Compressor Stocks?
Bike, pharma ingredient and compressor stocks are listed companies that build premium motorcycles and commercial vehicles, make active pharmaceutical ingredients and finished dosages, and build air compressors for factories and workshops. Their earnings depend on vehicle demand, medicine demand and industrial spending.
Bike, Pharma Ingredient and Compressor Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Eicher Motors | 7,549 | 193,538 | 33.5 | 23.4 | 22.0 | 0.02 |
| Granules India | 840.5 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
| Elgi Equipments | 578.45 | 17,259 | 38.5 | 44.4 | 19.3 | 0.24 |
On valuation, Granules India and Elgi Equipments trade at a P/E below the industry P/E, while Eicher Motors trades above it, which reflects the growth the market already expects. Readers comparing bike, pharma ingredient and compressor stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Bike, Pharma Ingredient and Compressor Stocks Have a Strong Roadmap in India?
Bike, pharma ingredient and compressor stocks have a strong roadmap in India because rising appetite for premium bikes, steady demand for essential medicines and growing factory investment keep widening the market for these companies.
- Motorcycles. Riders buy more premium bikes.
- Pharma ingredients. Medicine makers need reliable supply.
- Air compressors. Factories need efficient compressed air.
Why Eicher Motors Features Among These Bike, Pharma Ingredient and Compressor Stocks
Among the bike, pharma ingredient and compressor stocks on this list, Eicher Motors makes Royal Enfield motorcycles and, through a joint venture, commercial vehicles, and it sells mid-size motorcycles in India and in a growing list of overseas markets.
In the June 2026 quarter, revenue grew 29.4% year on year to Rs 7,099 crore, while net profit rose 21.3% to Rs 1,463 crore. Revenue rose from Rs 10,739 crore in FY22 to Rs 24,894 crore in FY26, a compound annual growth rate of 23.4%.
Net profit grew from Rs 1,677 crore in FY22 to Rs 5,515 crore in FY26, which works out to a compound annual growth rate of 34.7%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 193,538 crore. The stock trades at a P/E of 33.5, above the industry P/E of 23.4.
Roadmap: The company is launching new models, expanding its dealer and export network and entering electric motorcycles. A strong brand with loyal riders supports pricing and repeat demand.
What to watch: Follow new launches, export growth and the pace of electric and adventure model rollouts.
Why Granules India Features Among These Bike, Pharma Ingredient and Compressor Stocks
Among the premium bike, medicine ingredient and air compressor shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Why Elgi Equipments Features Among These Bike, Pharma Ingredient and Compressor Stocks
Among the three companies on this list, Elgi Equipments, based in Coimbatore, is a major manufacturer of air compressors for industrial customers, selling in India and in international markets through its own subsidiaries.
Revenue rose from Rs 2,580 crore in FY22 to Rs 4,068 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 178 crore in FY22 to Rs 430 crore in FY26, which works out to a compound annual growth rate of 24.6%.
In the June 2026 quarter, revenue grew 22.1% year on year to Rs 1,083 crore, while net profit rose 20.7% to Rs 103 crore. The company has a return on equity of 19.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 17,259 crore. The stock trades at a P/E of 38.5, below the industry P/E of 44.4.
Roadmap: The company is growing its oil-free and energy-efficient compressor range and building a service-led annuity through spares and aftermarket support. International units add geographic spread, and automation in manufacturing improves efficiency.
What to watch: Follow industrial capital spending trends and the contribution of international subsidiaries.
Eicher Motors vs Granules India vs Elgi Equipments on Key Financials
The table below sets the three bike, pharma ingredient and compressor stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Eicher Motors | 10,739 | 24,894 | 23.4% | 5,515 | 22.2% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
| Elgi Equipments | 2,580 | 4,068 | 12.1% | 430 | 10.6% |
Eicher Motors posts the highest return on equity in this group at 22.0%. Eicher Motors combines the largest FY26 revenue at Rs 24,894 crore with the fastest revenue growth, a 23.4% compound annual rate. A useful habit with bike, pharma ingredient and compressor stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Eicher Motors | 5,488 | 7,099 | 29.4% |
| Granules India | 1,226 | 1,479 | 20.6% |
| Elgi Equipments | 886 | 1,083 | 22.1% |
Key Risks to Check Before Investing in Bike, Pharma Ingredient and Compressor Stocks
Every theme carries risks that deserve a check before any decision. For these bike, pharma ingredient and compressor stocks, the main points are: Long-term premium bike, medicine ingredient and air compressor shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Demand cycles. Sales can vary with seasons and rates.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Production cycles. Vehicle output can vary with demand.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter bike, pharma ingredient and compressor stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Bike, Pharma Ingredient and Compressor Stocks
Bike, pharma ingredient and compressor stocks reward investors who follow demand trends, order books and margins together. Eicher Motors, Granules India and Elgi Equipments each have a clear plan to grow. Based on the 12 November 2026 close, Eicher Motors trades at Rs 7,549, Granules India at Rs 840.5 and Elgi Equipments at Rs 578.45. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these bike, pharma ingredient and compressor stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track bike, pharma ingredient and compressor stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are bike, pharma ingredient and compressor stocks?
Ans. Bike, pharma ingredient and compressor stocks are listed companies that build premium motorcycles and commercial vehicles, make active pharmaceutical ingredients and finished dosages, and build air compressors for factories and workshops. Their earnings depend on vehicle demand, medicine demand and industrial spending. This list looks at three of them, Eicher Motors, Granules India and Elgi Equipments, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.
Which bike, pharma ingredient and compressor stocks are covered in this list?
Ans. This list covers Eicher Motors, Granules India and Elgi Equipments. Based on the 12 November 2026 close, Eicher Motors traded at Rs 7,549, Granules India at Rs 840.5 and Elgi Equipments at Rs 578.45. Their return on equity ranges from 11.7% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 23.4%.
Why do bike, pharma ingredient and compressor stocks have a strong future roadmap in India?
Ans. Bike, pharma ingredient and compressor stocks have a strong roadmap in India because rising appetite for premium bikes, steady demand for essential medicines and growing factory investment keep widening the market for these companies. The main drivers are as follows. Motorcycles. Riders buy more premium bikes. Pharma ingredients. Medicine makers need reliable supply. Air compressors. Factories need efficient compressed air. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Eicher Motors performed financially?
Ans. Revenue rose from Rs 10,739 crore in FY22 to Rs 24,894 crore in FY26, a compound annual growth rate of 23.4%. Net profit grew from Rs 1,677 crore in FY22 to Rs 5,515 crore in FY26, which works out to a compound annual growth rate of 34.7%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 7,099 crore, while net profit rose 21.3% to Rs 1,463 crore. The company has a return on equity of 22.0%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 193,538 crore. The stock trades at a P/E of 33.5, above the industry P/E of 23.4. Looking ahead, the company is launching new models, expanding its dealer and export network and entering electric motorcycles. A strong brand with loyal riders supports pricing and repeat demand.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
How has Elgi Equipments performed financially?
Ans. Revenue rose from Rs 2,580 crore in FY22 to Rs 4,068 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 178 crore in FY22 to Rs 430 crore in FY26, which works out to a compound annual growth rate of 24.6%. In the June 2026 quarter, revenue grew 22.1% year on year to Rs 1,083 crore, while net profit rose 20.7% to Rs 103 crore. The company has a return on equity of 19.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 17,259 crore. The stock trades at a P/E of 38.5, below the industry P/E of 44.4. Looking ahead, the company is growing its oil-free and energy-efficient compressor range and building a service-led annuity through spares and aftermarket support. International units add geographic spread, and automation in manufacturing improves efficiency.
What risks should investors check before buying bike, pharma ingredient and compressor stocks?
Ans. Investors should check a few risks before buying bike, pharma ingredient and compressor stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of bike, pharma ingredient and compressor stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
